8-K: Current report filing
Published on September 26, 2008
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
Current
Report Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of
Report (Date of Earliest Event Reported): September 22, 2008
|
LIXTE
BIOTECHNOLOGY HOLDINGS,
INC.
|
|
(Exact
Name of Registrant as Specified in its
Charter)
|
|
Delaware
|
|
(State
or Other Jurisdiction of
Incorporation)
|
|
000-51476
|
20-2903526
|
|
|
(Commission
File Number)
|
(I.R.S.
Employer Identification
No.)
|
|
|
248
Route 25A, No. 2, East Setauket, New
York
|
11733
|
|
|
(Address
of Principal Executive
Offices)
|
(Zip
Code)
|
631-942-7959
(Registrant’s
Telephone Number, Including Area Code)
SRKP
7,
INC.
1900
Avenue of the Stars, Los Angeles, CA 90067\
(Former
Name or Former Address, if Changed Since Last Report)
.
Item
1.01 Entry
into a Material Agreement
On
September 22, 2008, the United States Public Health Service (“PHS”)
forwarded to Lixte Biotechnology, Inc. (the “Company”), a wholly owned
subsidiary of Lixte Biotechnology Holdings, Inc., a fully executed copy of
a
License Agreement between PHS and the Company. The effective date of the
Agreement is September 19, 2008. Pursuant to the Agreement, PHS has granted
an exclusive license of all of PHS’ rights in seven patent applications filed by
the Company. The majority of these patent applications are related to the use
of
certain compounds of the Company for the treatment of glioblastoma multiforme,
neuroblastoma, and medulloblastoma as well as the potential use of two
biomarkers as either diagnostic tests or in assays for the screening of
compounds for anti-cancer activity. The Company requested that PHS grant to
the
Company full rights to these inventions in order to develop processes, methods
or marketable products for public use and benefit. The Agreement provides for
an
initial license fee, minimum annual royalty payments, payments at various
milestones in the clinical development of the licensed compounds, and a
percentage of net sales of the licensed compounds.
1
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
LIXTE
BIOTECHNOLOGY HOLDINGS, INC.
|
||
| |
|
|
| Date: September 26, 2008 | By: | /s/ John S. Kovach |
|
John
S. Kovach, Chairman of the Board and Chief Executive Officer (principal
executive officer)
|
||
2